The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Nov 20

PMID 39564453

Authors

Tongwei Zeng

Yongqiang Xie

Keqiang Chai

Hui Sang

Affiliations

Soon will be listed here.

Abstract

In recent years, the incidence of prostate cancer has been increasing globally. Early stage of the disease can obtain a better clinical prognosis from surgery and endocrine therapy. The progression of advanced stage varies significantly between individuals, with some patients developing metastatic castration-resistant prostate cancer after standardized treatment. Therefore, staging of prostate cancer by accurate imaging is particularly important for the clinical management of patients. Simultaneously, the development of targeted therapy is also urgent for the treatment of advanced prostate cancer. Prostate specific membrane antigen as a prostate specific target has been widely used in the diagnosis and treatment of prostate cancer. This review summarizes the latest research progress of targeted prostate specific membrane antigen in the diagnosis and treatment of prostate cancer in detail, analyzes their value and challenges.

References

Wang X, Zhang Y, Ji Z, Yang P, Tian Y . Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and meta-analysis. World J Surg Oncol. 2021; 19(1):18. PMC: 7818761. DOI: 10.1186/s12957-021-02127-3. View

Savir-Baruch B, Werner R, Rowe S, Schuster D . PET Imaging for Prostate Cancer. Radiol Clin North Am. 2021; 59(5):801-811. DOI: 10.1016/j.rcl.2021.05.008. View

Zhang X, Sun S, Miao Y, Yuan Y, Zhao W, Li H . Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs. J Cancer Res Clin Oncol. 2022; 148(12):3511-3520. DOI: 10.1007/s00432-022-04248-y. View

Zhao R, Li Y, Nie L, Qin K, Zhang H, Shi H . The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan. Medicine (Baltimore). 2021; 100(15):e25417. PMC: 8052000. DOI: 10.1097/MD.0000000000025417. View

Bouchelouche K, Choyke P, Capala J . Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med. 2010; 9(44):55-61. PMC: 3410553. View

Weber J, Vogelzang N, Ernstoff M, Goodman O, Cranmer L, Marshall J . A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011; 34(7):556-67. PMC: 3709852. DOI: 10.1097/CJI.0b013e3182280db1. View

Pinto J, Suffoletto B, Berzin T, Qiao C, Lin S, Tong W . Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996; 2(9):1445-51. View

Tulsyan S, Das C, Tripathi M, Seth A, Kumar R, Bal C . Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun. 2017; 38(12):1094-1102. DOI: 10.1097/MNM.0000000000000749. View

Narayan V, Barber-Rotenberg J, Jung I, Lacey S, Rech A, Davis M . PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022; 28(4):724-734. PMC: 10308799. DOI: 10.1038/s41591-022-01726-1. View

10.

Theil G, Fischer K, Weber E, Medek R, Hoda R, Lucke K . The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study. PLoS One. 2016; 11(8):e0158354. PMC: 4968821. DOI: 10.1371/journal.pone.0158354. View

11.

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell P . Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. J Urol. 2016; 196(4):1261-7. DOI: 10.1016/j.juro.2016.02.3000. View

12.

Sadaghiani M, Sheikhbahaei S, Werner R, Pienta K, Pomper M, Gorin M . Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate. 2022; 82(7):826-835. PMC: 9311733. DOI: 10.1002/pros.24325. View

13.

Rizzo A, DallArmellina S, Pizzuto D, Perotti G, Zagaria L, Lanni V . PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?. Cancers (Basel). 2022; 14(16). PMC: 9406909. DOI: 10.3390/cancers14164039. View

14.

Jones W, Griffiths K, Barata P, Paller C . PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers (Basel). 2020; 12(6). PMC: 7352725. DOI: 10.3390/cancers12061367. View

15.

Liu X, Jiang T, Gao C, Liu H, Sun Y, Zou Q . Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis. Front Oncol. 2022; 12:911146. PMC: 9353183. DOI: 10.3389/fonc.2022.911146. View

16.

Vallabhajosula S, Nikolopoulou A, Babich J, Osborne J, Tagawa S, Lipai I . 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014; 55(11):1791-8. DOI: 10.2967/jnumed.114.140426. View

17.

von Eyben F, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K . Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2017; 45(3):496-508. PMC: 5787223. DOI: 10.1007/s00259-017-3895-x. View

18.

von Eyben F, Bauman G, von Eyben R, Rahbar K, Soydal C, Haug A . Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020; 21(23). PMC: 7730994. DOI: 10.3390/ijms21239054. View

19.

Yadav M, Ballal S, Sahoo R, Dwivedi S, Bal C . Radioligand Therapy With Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2019; 213(2):275-285. DOI: 10.2214/AJR.18.20845. View

20.

Maurer T, Gschwend J, Rauscher I, Souvatzoglou M, Haller B, Weirich G . Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2015; 195(5):1436-1443. DOI: 10.1016/j.juro.2015.12.025. View